BidaskClub cut shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a hold rating in a report published on Tuesday morning.
Several other research analysts have also commented on HALO. Zacks Investment Research lowered shares of Halozyme Therapeutics from a buy rating to a hold rating in a report on Monday, December 25th. BMO Capital Markets lifted their price target on shares of Halozyme Therapeutics from $14.00 to $15.00 and gave the company a market perform rating in a report on Friday, September 15th. Deutsche Bank lifted their price target on shares of Halozyme Therapeutics to $20.00 and gave the company a buy rating in a report on Friday, September 15th. Piper Jaffray Companies lifted their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an overweight rating in a report on Monday, October 16th. Finally, Canaccord Genuity lifted their price target on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a buy rating in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $19.14.
Halozyme Therapeutics (NASDAQ HALO) traded up $0.30 during midday trading on Tuesday, hitting $20.36. 802,413 shares of the stock traded hands, compared to its average volume of 1,240,000. Halozyme Therapeutics has a 1-year low of $10.74 and a 1-year high of $21.13. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. The firm has a market cap of $2,890.00, a price-to-earnings ratio of -29.94 and a beta of 2.09.
Institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $131,000. Prudential Financial Inc. boosted its stake in Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 940 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $171,000. Amalgamated Bank boosted its stake in Halozyme Therapeutics by 5.3% during the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 705 shares during the period. Finally, Suntrust Banks Inc. acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $186,000. 84.45% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/13/halozyme-therapeutics-halo-rating-lowered-to-hold-at-bidaskclub.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
What are top analysts saying about Halozyme Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halozyme Therapeutics and related companies.